1-(1-tert-butyl-1H-pyrazol-4-yl)ethanone | 1460286-48-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(1-tert-butyl-1H-pyrazol-4-yl)ethanone
• 英文别名: 1-(1-Tert-butyl-1h-pyrazol-4-yl)ethan-1-one；1-(1-tert-butylpyrazol-4-yl)ethanone
• CAS: 1460286-48-9
• 化学式: C₉H₁₄N₂O
• 分子量: 166.223
• InChiKey: STDCVUSTNUADIO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  34.9
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(1-tert-butyl-1H-pyrazol-4-yl)ethanone 在 pyridinium hydrobromide perbromide 作用下， 以 乙醇 为溶剂， 反应 24.0h， 生成 2-bromo-1-(1-tert-butyl-1H-pyrazol-4-yl)ethanone
  参考文献：
  名称：

  Syk 억제제

  摘要：

  This text appears to be a scientific or technical document discussing the therapeutic uses of a compound called Syk inhibitor in the treatment of various conditions including cancer and inflammatory diseases. It also mentions the chemical structure of the compound given by the chemical formula I. In the formula, X, X, X, R, R, R, R, and Y are as described in the specification. The document further provides methods for using these compounds and compositions containing compounds or salts thereof of the chemical formula I to treat conditions mediated by Syk.

  公开号：

  KR20160037198A
• 作为产物：
  描述：

  1-叔丁基吡唑 在 N-溴代丁二酰亚胺(NBS) 、 lithium chloro-isopropyl-magnesium chloride 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 4.5h， 生成 1-(1-tert-butyl-1H-pyrazol-4-yl)ethanone
  参考文献：
  名称：

  [EN] PYRAZOLYL-SUBSTITUTED HETEROARYLS AND THEIR USE AS MEDICAMENTS
  [FR] HÉTÉROARYLES À SUBSTITUTION PYRAZOLYLE ET LEUR UTILISATION EN TANT QUE MÉDICAMENTS

  摘要：

  该发明涉及新的取代杂环芳基化合物，其化学式为1或1'，其中A为N或CH，R2选自-C1-3-烷基，-C1-3-卤代烷基，F，Br，Cl，Y选自-O-或-CH2-，R3如权利要求1所定义，以及其药用盐，以及这些化合物用于治疗哮喘、慢性阻塞性肺病、过敏性鼻炎、过敏性皮炎、红斑狼疮、红斑狼疮性肾炎和类风湿性关节炎等疾病。

  公开号：

  WO2017042100A1

文献信息

• [EN] BICYCLIC PYRAZINONE DERIVATIVES<br/>[FR] DÉRIVÉS BICYCLIQUES DE PYRAZINONE
  申请人：MERCK PATENT GMBH

  公开号：WO2013143663A1

  公开（公告）日：2013-10-03

  Compounds of the formula (I) in which R1, X and Y have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.

  式(I)中R1、X和Y具有权利要求1中指示的含义的化合物是坦克酶的抑制剂，可用于治疗癌症、心血管疾病、中枢神经系统损伤和不同形式的炎症等疾病。
• KINASE INHIBITORS
  申请人：Respivert Limited

  公开号：US20170291917A1

  公开（公告）日：2017-10-12

  There are provided compounds of formula I, wherein T, A, Q, Z, G, R 4 , R 5a , R 5b and n have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

  提供了化合物I的公式，其中T、A、Q、Z、G、R4、R5a、R5b和n的含义如描述中所示，这些化合物具有抗炎活性（例如，通过抑制p38丝裂原活化蛋白激酶酶家族中的一个或多个成员；Syk激酶；以及酪氨酸激酶Src家族的成员之一）并且在治疗中有用，包括在药物组合中，特别是用于治疗炎症性疾病，包括肺部、眼睛和肠道的炎症性疾病。
• SYK INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：US20150038488A1

  公开（公告）日：2015-02-05

  The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I wherein X 1 , X 2 , X 3 , R 2 , R 3 , R 4 , R 5 , and Y are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.

  本公开涉及的化合物是Syk抑制剂，并且适用于治疗各种疾病状态，包括癌症和炎症性疾病。在特定实施例中，化合物的结构由公式I给出，其中X1、X2、X3、R2、R3、R4、R5和Y如本文所述。本公开进一步提供了包括公式I的化合物或其药学上可接受的盐的制药组合物，以及使用这些化合物和组合物治疗Syk介导的疾病的方法。
• BICYCLIC PYRAZINONE DERIVATIVES
  申请人：Merck Patent GmbH

  公开号：US20150057264A1

  公开（公告）日：2015-02-26

  Compounds of the formula I in which R 1 , X and Y have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.

  公式I中，R1、X和Y的含义如权利要求1所示的化合物是Tankyrase的抑制剂，可以用于治疗癌症、心血管疾病、中枢神经系统损伤和不同形式的炎症等疾病。
• Substituted pyrrolo[1,2-A]pyrazin-1-ones and pyrazolo[1,5-A]pyrazin-4-ones as inhibitors of tankyrase and poly(ADP-ribose)polymerase activity
  申请人：Merck Patent GmbH

  公开号：US09120805B2

  公开（公告）日：2015-09-01

  Compounds of the formula I in which R1, X and Y have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.

  公式I中，R1、X和Y具有声明1中所示的含义的化合物是坦克酰酶抑制剂，可用于治疗癌症、心血管疾病、中枢神经系统损伤和不同形式的炎症等疾病。